o-Ethyl O-(4-(methylthio)phenyl) methylphosphonothioate
- Phosphonothioic acid, methyl-, O-ethyl O-(4-(methylthio)phenyl) ester
Registry Numbers and Inventories.
Agricultural Chemical and Pesticide
Swiss Giftliste 1
Boiling point, °C
102 (0.01 torr)
1.193 g/cm3 (20 C)
Hazards and Protection.
Keep in a cool, dry, dark location in a tightly sealed container or cylinder. Keep away from incompatible materials, ignition sources and untrained individuals. Secure and label area. Protect containers/cylinders from physical damage.
All chemicals should be considered hazardous. Avoid direct physical contact. Use appropriate, approved safety equipment. Untrained individuals should not handle this chemical or its container. Handling should occur in a chemical fume hood.
Chemical splash goggles in compliance with OSHA regulations are advised; however, OSHA regulations also permit other type safety glasses. Whre chemical resistant gloves. To prevent repeated or prolonged skin contact, wear impervious clothing and boots.
Respiratory protection (supplied-air respirator with full facepiece or self-contained breathing apparatus) should be available where these compounds are manufactured or used and should be worn in case of emergency and overexposure.
Evacuate area and ventilate. Wear protective equipment. If required, use an inert absrobent. Sweep up and place in an appropriate container for disposal. Wash contaminated surfaces.
Strong oxidizing agents.
Wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Use agent most appropriate to extinguish fire.
When heated to decomp, can emit highly toxic fumes of oxides of phosphorous.
Headache, dizziness, muscle spasms, and profound weakness are common. Alterations of level of consciousness, seizures and coma may occur. Seizures may be more common in children. Peripheral neuropathy of the mixed sensory-motor type may be delayed in onset by 6 to 21 days. Recovery may be slow or incomplete. Most of the organophosphates have not been teratogenic in experimental animals, but some have caused lower fetal or birth weights and/or higher neonatal mortality. <br>Sporadic reports of human birth defects related to organophosphates have not been verified.
Vomiting, diarrhea, fecal incontinence, and abdominal pain may occur.
Dyspnea, rales, bronchorrhea, or tachypnea may be noted. Pulmonary edema may occur in severe cases.
Sweating is a consistent but not universal sign.
Seek medical attention. If individual is drowsy or unconscious, do not give anything by mouth; place individual on the left side with the head down. Contact a physician, medical facility, or poison control center for advice about whether to induce vomiting. If possible, do not leave individual unattended.
Move patient to fresh air. Monitor for respiratory distress. If cough or difficulty breathing develops, evaluate for respiratory tract irritation, bronchitis, or pneumonitis. Administer oxygen and assist ventilation as required. Treat bronchospasm with beta2 agonist and corticosteroid aerosols.
Systemic effects can occur from dermal exposure to organophosphates. Remove contaminated clothing, wash skin, hair and nails vigorously with repeated soap washings. Leather absorbs pesticides; all contaminated leather should be discarded. Rescue personnel and bystanders should avoid direct contact with contaminated skin, clothing, or other objects. Treatment should include recommendations listed in the oral exposure section when appropriate. Some chemicals can produce systemic poisoning by absorption through intact skin. Carefully observe patients with dermal exposure for the development of any systemic signs or symptoms and administer symptomatic treatment as necessary. Contraindications - succinylcholine and other cholinergic agents are contraindicated.
Irrigate exposed eyes with copious amounts of tepid water for at least 15 minutes. If irritation, pain, swelling, lacrimation, or photophobia persist, the patient should be seen in a health care facility. Patients symptomatic following exposure should be observed in a controlled setting until all signs and symptoms have fully resolved. Suction oral secretions until atropinization. Treatment should include recommendations listed in the oral exposure section when appropriate. Contraindications - succinylcholine and other cholinergic agents are contraindicated.